


PHARMACEUTICAL INSTITUTE (PHI) COMPLETES ACQUISITION BY KELIX BIO

Posted on 27 July 2022



Categories: [Deal & transactions](#), [Healthcare](#), [Pharma & Life Sciences](#), [Other](#)

Tags: [Allen & Overy](#), [dx1](#), [Laurent Sablé](#), [Naciri & Associés](#), [UGGC Africa](#)



KELIX bio, a pan-African biopharmaceutical platform, has entered into a binding agreement to acquire Moroccan Pharmaceutical Institute (“PHI”).

This investment marks KELIX bio's first entry into Morocco – an important market in the company's strategy – at a time when the Kingdom is accelerating the successful rollout of AMO (Assurance Maladie Obligatoire), a far-reaching plan to provide universal health coverage to Moroccans.

Founded in 1988, PHI has expertise in manufacturing, promoting, and importing pharmaceutical products.

[UGGC Africa](#) advised Pharmaceutical Institute (PHI) in this agreement with partner **Laurent Sablé** (pictured).

Naciri & Associés [Allen & Overy](#) acted as legal counsel and Sijilmasa (**Amine Rezzouk**) acted on the financial aspects of the deal.